The availability of effective antiviral therapy for most clinically significant myxovirus infections is limited. Licensed neuraminidase inhibitors for influenza therapy, Zanamivir and Oseltamivir, show efficacy when administered within a 48-hour window after the onset of symptoms, but are increasingly compromised by preexisting or emerging viral resistance [6, 7, 8] . Ribavirin, although approved for RSV treatment, shows limited utility due to efficacy and toxicity issues [9] . The polyclonal immunoglobulin RSV-IVIG [10] and the humanized monoclonal antibody Synagis [11] provide RSV prophylaxis, but use is limited to high-risk pediatric patients. Considering the high mutation rates seen in particular with RNA viruses [12, 13] , the development of novel types of myxovirus inhibitors that circumvent the rapid development of resistance is highly desirable.